SOURCE: Oxford Biomedica Plc

May 16, 2005 07:00 ET

OXFORD BIOMEDICA PLC ANNOUNCES - PHASE II TRIALS OF TROVAX

OXFORD, UK -- (MARKET WIRE) -- May 16, 2005 --FOR IMMEDIATE RELEASE 16 MAY 2005


     OXFORD BIOMEDICA PRESENTS UPDATED AND ENCOURAGING TROVAX(R) 
   PHASE II RESULTS IN COLORECTAL CANCER AT THE 2005 ANNUAL MEETING

Oxford, UK: 16 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy company, today announced that new and encouraging data were presented from the Phase II trials of TroVax, its cancer immunotherapy, in colorectal cancer at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, in Orlando, Florida, USA, on Sunday, 15 May 2005.

The presentation included data reported in March 2005 from the two Phase II trials in first line treatment of metastatic colorectal cancer alongside irinotecan-based (IFL) and oxaliplatin-based (FOLFOX) chemotherapy. In addition, further immune response data were presented. These show that the maximum antibody levels (titres) targeted against the 5T4 tumour antigen in the Phase II studies are significantly higher than in the Phase I/II trial in post-chemotherapy patients. Peak titres reached levels of 5,000 in the TroVax+IFL trial and 1,200 in the TroVax+FOLFOX trial. These are four- to ten-fold higher than in the Phase I/II study. This may be important because, in that earlier study, there was a highly significant (p<0.0001) correlation between antibody titre and time to disease progression amongst responders.

Additional new data include analysis of the anti-5T4 killer T-cell (CD8) response following immunisation with TroVax. Killer T-cells are widely believed to be important antitumour cells. Encouragingly, 83% of patients in the TroVax+IFL study and 71% in the TroVax+FOLFOX trial developed anti-5T4 killer T-cells, reaching levels as high as 1 in 1,000 white blood cells. This level is comparable with those seen in viral infections that are cleared by circulating antiviral killer cells. Interestingly, in the TroVax+FOLFOX trial, the two patients that showed complete tumour responses (tumour clearance) had the highest antibody and killer T-cells levels. This links, as in the Phase I/II trial, the anticancer immunological effect of TroVax immunisation to clinical benefit.

As previously reported, the primary endpoints in the two trials of safety and immunological responses were achieved. All 25 patients that have reached the interim stage of the trial have shown an immune response to the 5T4 tumour antigen. In addition, the secondary endpoint of clinical benefit exceeded expectation. Eighteen of 19 evaluable patients responded to treatment. Whilst five patients had disease stabilisation following treatment, 13 of the 19 patients (68%) were defined as clinical responders according to industry standard criteria, comprising three complete and ten partial responses.

Two independent studies of the chemotherapy regimens alone reported clinical response rates in evaluable patients of 41% and 50% respectively (Douillard et al., The Lancet 2000, vol 355, pp 1041-1047; de Gramont et al., Journal of Clinical Immunology 2000, vol 18, pp2938 -2947). However, a precise comparison with the TroVax trials is not possible owing to differences in the trial protocols and patient numbers.

Enrolment in the trials was completed in September 2004 with 36 patients recruited. The trials are on track to report full safety and immunological data as well as final audited tumour response statistics in the second half of 2005. Patient survival, which can be compared to historical controls, will be reported once the median survival has been reached in the two trials. This is anticipated in early 2006.

This ASCO abstract on the TroVax Phase II results may be accessed online at http://www.asco.org at the conclusion of the meeting on 17 May. The abstract title is as follows:

"An Open Label Phase II Study of MVA Expressing the Tumour Antigen 5T4 Given in Conjunction with Chemotherapy: Safety and Immunogenicity Before, During and After Chemotherapy." (Abstract #30642)

Commenting on the ASCO presentation of TroVax Phase II results, Oxford BioMedica's Chief Scientific Officer, Dr Sue Kingsman, said: "We are very pleased with the new data from the TroVax Phase II trials. Given what we know from the previous colorectal cancer trial, we are hopeful that the stronger anti-5T4 responses in the first line treatment setting will lead to a corresponding extension of time to disease progression and survival. Based on current data, we are optimistic that TroVax will have a role to play in the treatment of colorectal cancer and we look forward to this being evaluated in pivotal clinical studies".

-Ends-


For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive        Tel: +44 (0)1865 783 000
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ 
Mary-Jane Johnson Buchanan                      Tel: +44 (0)20 7466 5000
Communications
Scientific/Trade Press Enquiries:

Sue Charles/ Katja Stout/ Ashley Lilly          Tel: +44 (0)20 7886 8150
Northbank Communications

Notes to editors:

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company's lead product is a gene therapy for Parkinson's disease, which is expected to enter clinical trials in early 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co and Biogen Idec.

Further information is available at www.oxfordbiomedica.co.uk.

2. TroVax® cancer immunotherapy

TroVax is Oxford BioMedica's leading cancer immunotherapy product. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a poxvirus (MVA) gene transfer system, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 protein.

In Phase I/II trials in late stage colorectal cancer patients, TroVax was safe and well tolerated; patients mounted an anti-5T4 immune response; and the immune response correlated, with high significance, to time to disease progression, which translated into a correlation with improved overall survival.

Four Phase II trials are underway. Positive initial data from trials investigating TroVax in colorectal cancer in combination with first line standard of care treatment and as a (neo) adjuvant to surgery were released in March 2005. The primary endpoints of safety and immunological responses were achieved. In the two trials of TroVax alongside chemotherapy, the secondary endpoint of tumour response rate exceeded expectation.

A further Phase II trial is ongoing in renal cell carcinoma, and the US National Cancer Institute, through the Southwest Oncology Group, is planning a Phase II trial in breast cancer.

3. ASCO

The American Society of Clinical Oncology is the world's leading professional organisation representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different cancers that strike millions of people around the world every year.


                    This information is provided by RNS
            The company news service from the London Stock Exchange